RXRX — RECURSION PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1601830 ·
Last close
$3.25
Market Cap
$1.74B
52W High
$4.09
52W Low
$2.84
ADV30
17,729,372
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,303,000 | -4,188,000 | -134,968,000 | -131,005,000 | 1,212,668,000 | 545,683,000 | 297,665,000 |
| Mar 2026 | 6,301,000 | -6,189,000 | -128,505,000 | -117,504,000 | 1,339,522,000 | 654,473,000 | 314,753,000 |
| Dec 2025 | 35,351,000 | 21,076,000 | -108,334,000 | -108,122,000 | 1,474,130,000 | 743,294,000 | 343,265,000 |
| Sep 2025 | 4,983,000 | -9,704,000 | -172,202,000 | -162,253,000 | 1,399,526,000 | 659,836,000 | 352,578,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-350,481,000
Investing CF
$-6,090,000
Financing CF
$378,609,000
CapEx
$-3,784,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,324,511,000
Inventory
—
Receivables
$14,393,000
ST Investments
—
EBIT TTM
$-521,984,000
Pretax Income TTM
$-523,465,000
Interest Exp TTM
$1,481,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,856,000
EBITDA
$-471,604,000
Free Cash Flow
$-219,493,744
Enterprise Value
$1,260,817,024
Total Cash
$545,683,008
Total Debt
$66,638,000
Shares Out
535,342,170
Trailing EPS
$-0.93
Book Value
$1.71
ROE
-56.6%
ROA
-27.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,256,000 | -648,132,000 | -644,759,000 | 1,474,130,000 | 343,265,000 | — | -371,808,000 |
| Dec 2024 | 58,488,000 | -479,004,000 | -463,661,000 | 1,448,598,000 | 413,816,000 | — | -359,174,000 |
| Dec 2023 | 43,876,000 | -350,060,000 | -328,066,000 | 653,699,000 | 190,263,000 | — | -287,780,000 |
| Dec 2022 | 39,681,000 | -245,727,000 | -239,476,000 | 701,288,000 | 215,482,000 | — | -83,524,000 |
TTM Snapshot
Revenues TTM
$52,309,000
NetIncome TTM
$-296,732,000
OpCashFlow TTM
$0
Assets (Latest)
$1,448,598,000
Forward EPS
$-0.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VIR | Vir Biotechnology, Inc. | $1.68B | $9.91 | — |
| MAZE | Maze Therapeutics, Inc. | $1.64B | $29.60 | — |
| ALVO | Alvotech | $1.87B | $5.25 | — |
| IMCR | Immunocore Holdings plc | $1.89B | $36.61 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.95B | $5.97 | — |
News headlines (Yahoo Finance, 1h cache)
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
2026-08-18 07:43 · Yahoo
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
2026-08-17 15:01 · Yahoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
2026-08-17 05:01 · Yahoo
These Are the Stocks Wall Street Is Betting Against the Most
2026-08-12 19:30 · Yahoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript
2026-08-12 13:59 · Yahoo
Recursion Pharmaceuticals Q2 Earnings Call Highlights
2026-08-05 19:04 · Yahoo
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update
2026-08-05 12:12 · Yahoo
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-07-29 21:45 · Yahoo
Recursion to Participate in Upcoming Investor Conferences
2026-08-04 12:00 · Yahoo
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
2026-08-17 13:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.